Mirabegron in the treatment of overactive bladder

Maggiore, Umberto Leone Roberti; Cardozo, Linda; Ferrero, Simone; Sileo, Filomena Giulia; Cola, Alice; Torella, Annalaura; Colacurci, Nicola; Candiani, Massimo; Salvatore, Stefano

doi:10.1517/14656566.2014.898752

Cited by 12 publications

(2 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common side-effects of b3-adrenoreceptor agonists include headache, tachycardia, and gastrointestinal symptoms. Six large, randomized trials have evaluated the efficacy and adverse effects of mirabegron compared with placebo (or an active control group) and showed that mirabegron is efficacious and safe in treating patients with OAB [17][18][19]. The clinical results were in line with those observed with well-established antimuscarinic treatments.…”

Section: B3-adrenoreceptor Agonistsmentioning

confidence: 69%

Oral Pharmacologic Management of Overactive Bladder Syndrome: Where Do We Stand?

Marcelissen

Rashid

Lopes

et al. 2019

European Urology Focus

View full text Add to dashboard Cite

Overactive bladder syndrome (OAB) is a prevalent disorder with a significant impact on quality of life. Despite this high prevalence, there is significant underdiagnosis and undertreatment due to several barriers, including embarrassment, poor communication and low patient adherence. Currently, various antimuscarinic are available in the treatment of OAB. The introduction of mirabegron has broadened the therapeutic approach and combination therapy of both agents can be valuable in clinical practice. Yet, patient adherence to most drugs for OAB is still relatively poor. Healthcare providers need to identify and utilise strategies to improve treatment adherence by defining clear treatment goals, implement educational methods and frequently communicate with patients to identify problems with adherence. The elderly population form need special attention as in these patients, anticholinergics should be prescribed with care and adequate knowledge regarding pharmacokinetics and drug interactions in essential. Furthermore, patient expectations should be clearly discussed. In this narrative review, the current advances in oral pharmacotherapy are evaluated and the most important factors involved in the management of OAB are discussed.

show abstract

Section: B3-adrenoreceptor Agonistsmentioning

confidence: 69%

Oral Pharmacologic Management of Overactive Bladder Syndrome: Where Do We Stand?

Marcelissen

Rashid

Lopes

et al. 2019

European Urology Focus

View full text Add to dashboard Cite

show abstract

“…We screened 15 full-text articles, and excluded 9 studies that did not meet the inclusion criteria. Seven studies were non randomized study [ 20 21 22 23 24 25 26 ] and 2 studies included a wrong population (i.e., patients with idiopathic detrusor overactivity) [ 27 28 ]. The assessment process is illustrated in the PRISMA flowchart ( Fig.…”

Section: Resultsmentioning

confidence: 99%

Safety and efficacy of beta-3 adrenergic agonists in treating neurogenic lower urinary tract dysfunction: A systematic review and meta-analysis

Elkhashab,

Alqahtani,

Kim

et al. 2024

Investig Clin Urol

View full text Add to dashboard Cite

Purpose To evaluate efficacy and safety of beta-3 adrenergic agonists in adults with neurogenic lower urinary tract dysfunction. Materials and Methods According to a protocol (CRD42022350079), we searched multiple data sources for published and unpublished randomized controlled trials (RCTs) up to 2nd August 2022. Two review authors independently screened studies and abstracted data from the included studies. We performed statistical analyses by using a random-effects model and interpreted them according to the Cochrane Handbook for Systematic Reviews of Interventions. We used GRADE guidance to rate the certainty of evidence (CoE). Results We found data to inform two comparisons: beta-3 adrenergic agonists versus placebo (4 RCTs) and anticholinergics (2 RCTs). Only mirabegron was used for intervention in all included studies. Compared to placebo, beta-3 adrenergic agonists may have a clinically unimportant effect on urinary symptoms score (mean difference [MD] -2.50, 95% confidence interval [CI] -4.78 to -0.22; I 2 =92%; 2 RCTs; 192 participants; low CoE) based on minimal clinically important difference of 3. We are very uncertain of the effects of beta-3 adrenergic agonists on quality of life (MD 10.86, 95% CI 1.21 to 20.50; I 2 =41%; 2 RCTs; 98 participants; very low CoE). Beta-3 adrenergic agonists may result in little to no difference in major adverse events (cardiovascular adverse events) (risk ratio 0.57, 95% CI 0.14 to 2.37; I 2 =0%; 4 RCTs; 310 participants; low CoE). Compared to anticholinergics, no study reported urinary symptom scores and quality of life. There were no major adverse events (cardiovascular adverse events) in either study group (1 study; 60 participants; very low CoE). Conclusions Compared to placebo, beta-3 adrenergic agonists may have similar effects on urinary symptom scores and major adverse events. There were uncertainties about their effects on quality of life. Compared to anticholinergics, we are either very uncertain or have no evidence about urinary symptom scores, quality of life, and major adverse events.

show abstract

Individualizing Drug Therapy

Palmerola

Νitti

2018

Contemporary Pharmacotherapy of Overactive Bladder

View full text Add to dashboard Cite

Mirabegron in the treatment of overactive bladder

Cited by 12 publications

References 68 publications

Oral Pharmacologic Management of Overactive Bladder Syndrome: Where Do We Stand?

Oral Pharmacologic Management of Overactive Bladder Syndrome: Where Do We Stand?

Safety and efficacy of beta-3 adrenergic agonists in treating neurogenic lower urinary tract dysfunction: A systematic review and meta-analysis

Individualizing Drug Therapy

Contact Info

Product

Resources

About